{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:51:37Z","timestamp":1791517897007,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ningbo Top Medical and Health Research Program","award":["2022030410"],"award-info":[{"award-number":["2022030410"]}]},{"name":"Suzhou Clinical Medical Center for Mood Disorders","award":["Szlcyxzx202109"],"award-info":[{"award-number":["Szlcyxzx202109"]}]},{"name":"Suzhou Key Laboratory","award":["SZS2024016"],"award-info":[{"award-number":["SZS2024016"]}]},{"name":"Multicenter Clinical Research on Major Diseases in Suzhou","award":["DZXYJ202413"],"award-info":[{"award-number":["DZXYJ202413"]}]},{"name":"Medical Scientific Research Project of Yangzhou Municipal Health Commission","award":["2023-2-35"],"award-info":[{"award-number":["2023-2-35"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-08396-0","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:35:55Z","timestamp":1783766155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bone mineral density, prolactin, estradiol, testosterone levels and related research in male chronic patients with schizophrenia"],"prefix":"10.1186","volume":"26","author":[{"given":"Pan","family":"Jing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinmei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"8396_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2023.173554","author":"KY Huang","year":"2023","unstructured":"Huang KY, Huang YJ, Chen SJ, et al. The associations between cognitive func tions and TSNAX genetic variations in patients with schizophrenia. Pharmacol Biochem Behav. 2023. https:\/\/doi.org\/10.1016\/j.pbb.2023.173554.","journal-title":"Pharmacol Biochem Behav"},{"issue":"10039","key":"8396_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","volume":"388","author":"MJ Owen","year":"2016","unstructured":"Owen MJ, Sawa A, Mortensen PB. Schizophrenia Lancet. 2016;388(10039):86\u201397.","journal-title":"Schizophrenia Lancet"},{"key":"8396_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12991-015-0079-6","volume":"14","author":"A Akinsulore","year":"2015","unstructured":"Akinsulore A, Mapayi BM, Aloba OO, et al. Disability assessment as an outcome measure: a comparative study of Nigerian outpatients with schizophrenia and healthy control. Ann Gen Psychiatry. 2015;14:40.","journal-title":"Ann Gen Psychiatry"},{"issue":"18","key":"8396_CR4","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1056\/NEJMra1808803","volume":"381","author":"SR Marder","year":"2019","unstructured":"Marder SR, Cannon TD, Schizophrenia. N ENGL J MED. 2019;381(18):1753\u201361.","journal-title":"N ENGL J MED"},{"key":"8396_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-01949-9","author":"RA McCutcheon","year":"2023","unstructured":"McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophre nia: aetiology, pathophysiology, and treatment. Mol Psychiatry. 2023. https:\/\/doi.org\/10.1038\/s41380-023-01949-9.","journal-title":"Mol Psychiatry"},{"key":"8396_CR6","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","volume":"386","author":"Collaborators GBoDS","year":"2015","unstructured":"Collaborators GBoDS. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013 a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743\u2013800.","journal-title":"Lancet"},{"key":"8396_CR7","first-page":"2053","volume":"380","author":"JA Salomon","year":"2013","unstructured":"Salomon JA, Wang H, Freeman MK, et al. The global burden of disease study 2010. Lancet. 2013;380:2053\u2013260.","journal-title":"Lancet"},{"key":"8396_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","volume":"10","author":"MD Hert","year":"2011","unstructured":"Hert MD, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52\u201377.","journal-title":"World Psychiatry"},{"key":"8396_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s11657-014-0182-3","volume":"9","author":"SW Wade","year":"2014","unstructured":"Wade SW, Strader C, Fitzpatrick LA, et al. Estimating prevalence of osteoporosis: examples from industrialized countries. Arch Osteoporos. 2014;9:182\u201392.","journal-title":"Arch Osteoporos"},{"issue":"2","key":"8396_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.genhosppsych.2015.01.004","volume":"37","author":"B Stubbs","year":"2015","unstructured":"Stubbs B, Gaughran F, Mitchell AJ, et al. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Gen Hosp Psychiatry. 2015;37(2):126\u201333.","journal-title":"Gen Hosp Psychiatry"},{"issue":"1","key":"8396_CR11","first-page":"64","volume":"29","author":"JR Bostwick","year":"2008","unstructured":"Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-Induced Hyperprolactinemia Pharmacotherapy. 2008;29(1):64\u201373.","journal-title":"Antipsychotic-Induced Hyperprolactinemia Pharmacotherapy"},{"key":"8396_CR12","first-page":"255","volume":"28","author":"SD Bulut","year":"2016","unstructured":"Bulut SD, Bulut S, Atalan DG, et al. The Effect of Antipsychotics on Bone Mineral Density and Sex Hormones in Male Patients with Schizophrenia. Psychiatria Danubina. 2016;28:255\u201362.","journal-title":"Psychiatria Danubina"},{"issue":"8","key":"8396_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2165\/00023210-200721080-00003","volume":"21","author":"U Halbreich","year":"2007","unstructured":"Halbreich U, Osteoporosis. Schizophrenia and Antipsychotics: The Need for a Comprehensive Multifactorial Evaluation. CNS Drugs. 2007;21(8):641\u201357.","journal-title":"CNS Drugs"},{"issue":"1","key":"8396_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.abb.2010.07.006","volume":"503","author":"BL Clarke","year":"2010","unstructured":"Clarke BL, Khosla S. Female reproductive system and bone. Arch Biochem Biophys. 2010;503(1):118\u201328.","journal-title":"Arch Biochem Biophys"},{"key":"8396_CR15","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1210\/jc.2009-0417","volume":"94","author":"PM Cawthon","year":"2009","unstructured":"Cawthon PM, Ensrud KE, Laughlin GA, et al. Sex Hormones and Frailty in Older Men: The Osteoporotic Fractures in Men (MrOS) Study. J Clin Endocrinol Metab. 2009;94:3806\u201315.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Pt A","key":"8396_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.steroids.2014.12.010","volume":"99","author":"JA Cauley","year":"2015","unstructured":"Cauley JA. Estrogen and bone health in men and women. Steroids. 2015;99(Pt A):11\u20135.","journal-title":"Steroids"},{"issue":"12","key":"8396_CR17","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1210\/jc.2011-0312","volume":"96","author":"ES LeBlanc","year":"2011","unstructured":"LeBlanc ES, Wang PY, Lee CG, et al. Higher testosterone levels are associated with less loss of lean body mass in older men. J Clin Endocrinol Metab. 2011;96(12):3855\u201363.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"8396_CR18","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jbmr.2164","volume":"29","author":"NE Lane","year":"2014","unstructured":"Lane NE, Parimi N, Lui L-Y, et al. Association of Serum Uric Acid and Incident Nonspine Fractures in Elderly Men: The Osteoporotic Fractures in Men (MrOS) Study. J Bone Miner Res. 2014;29(7):1701\u20137.","journal-title":"J Bone Miner Res"},{"key":"8396_CR19","unstructured":"Association AP. Diagnostic and statistical manual of mental disorders, fifth ed. DSM-5. 2013."},{"key":"8396_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261\u201376.","journal-title":"Schizophr Bull"},{"issue":"3","key":"8396_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11914-014-0215-2","volume":"12","author":"B Gong","year":"2014","unstructured":"Gong B, Mandair GS, Wehrli FW, et al. Novel assessment tools for osteoporosis diagnosis and treatment. Curr Osteoporos Rep. 2014;12(3):357\u201365.","journal-title":"Curr Osteoporos Rep"},{"issue":"8","key":"8396_CR22","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.clinthera.2015.06.006","volume":"37","author":"MT Drake","year":"2015","unstructured":"Drake MT, Clarke BL, Lewiecki EM. The Pathophysiology and Treatment of Osteoporosis. Clin Ther. 2015;37(8):1837\u201350.","journal-title":"Clin Ther"},{"issue":"4","key":"8396_CR23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/JCP.0b013e318221b123","volume":"31","author":"D-U Jung","year":"2011","unstructured":"Jung D-U, Kelly DL, Oh M-K, et al. Bone mineral density and osteoporosis risk in older patients with schizophrenia. J Clin Psychopharmacol. 2011;31(4):406\u201310.","journal-title":"J Clin Psychopharmacol"},{"key":"8396_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/hup.2387","volume":"29","author":"M Wang","year":"2014","unstructured":"Wang M, Hou R, Jian J, et al. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Hum Psychopharmacol Clin Exp. 2014;29:183\u20139.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"8396_CR25","doi-asserted-by":"crossref","unstructured":"Shen Y, Li Z, Huang Y, et al. Prevalence and factors associated with decreased bone mineral density in young and middle-aged male schizophrenic patients. J Osteoporos Phys Activity. 2017;05(01).","DOI":"10.4172\/2329-9509.1000189"},{"issue":"3","key":"8396_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000329391","volume":"94","author":"M Doknic","year":"2011","unstructured":"Doknic M, Maric NP, Britvic D, et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology. 2011;94(3):246\u201354.","journal-title":"Neuroendocrinology"},{"key":"8396_CR27","doi-asserted-by":"crossref","unstructured":"Tseng PT, Chen YW, Yeh PY et al. Bone mineral density in schizophrenia: an update of current meta-analysis and literature review under guideline of PRISMA. Medicine (Baltimore), 2015, 94(47): e1967.","DOI":"10.1097\/MD.0000000000001967"},{"issue":"6","key":"8396_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1517\/14740338.2016.1167873","volume":"15","author":"MD Hert","year":"2016","unstructured":"Hert MD, Detraux J, Stubbs B. Relationship between antipsychotic medication, serum prolactin levels and osteoporosis\/osteoporotic fractures in patients with schizophrenia: a critical literature review. Exp Opin Drug Saf. 2016;15(6):809\u201323.","journal-title":"Exp Opin Drug Saf"},{"issue":"5","key":"8396_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40263-014-0157-3","volume":"28","author":"J Peuskens","year":"2014","unstructured":"Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421\u201353.","journal-title":"CNS Drugs"},{"issue":"1\u20133","key":"8396_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.schres.2014.05.009","volume":"157","author":"K Okita","year":"2014","unstructured":"Okita K, Kanahara N, Nishimura M, et al. Second-generation antipsychotics and bone turnover in schizophrenia. Schizophr Res. 2014;157(1\u20133):137\u201341.","journal-title":"Schizophr Res"},{"key":"8396_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/2045125312442080","volume":"2","author":"JR Bishop","year":"2012","unstructured":"Bishop JR, Rubin LH, Reilly JL, et al. Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment. Ther Adv Psychopharmacol. 2012;2:95\u2013102.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"3","key":"8396_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.9758\/cpn.2019.17.3.333","volume":"17","author":"J Lally","year":"2019","unstructured":"Lally J, Sahl AB, Murphy KC, et al. Serum Prolactin and Bone Mineral Density in Schizophrenia: A Systematic Review. Clin Psychopharmacol Neurosci. 2019;17(3):333\u201342.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"8396_CR33","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.comppsych.2016.06.005","volume":"69","author":"SD Bulut","year":"2016","unstructured":"Bulut SD, Bulut S, G\u00fcriz O. The relationship between sex hormone profiles and symptoms of schizophrenia in men. Compr Psychiatr. 2016;69:186\u201392.","journal-title":"Compr Psychiatr"},{"issue":"2","key":"8396_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00004714-200204000-00002","volume":"22","author":"S Smith","year":"2002","unstructured":"Smith S, Wheeler MJ, Murray R, et al. The Effects of Antipsychotic-Induced Hyperprolactinaemia on the Hypothalamic-Pituitary-Gonadal Axis. J Clin Psychopharmacol. 2002;22(2):109\u201314.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"8396_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3371\/CSRP.KISE.020113","volume":"7","author":"BJ Kinon","year":"2013","unstructured":"Kinon BJ, Liu-Seifert H, Stauffer VL, et al. Bone Loss Associated with Hyperprolactinemia in Patients with Schizophrenia: Are there Gender Differences? Clin Schizophr Relat Psychos. 2013;7(3):115\u201323.","journal-title":"Clin Schizophr Relat Psychos"},{"key":"8396_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0924-9338(13)76427-7","volume":"28","author":"SK Agarwal","year":"2013","unstructured":"Agarwal SK. 1382 \u2013 High prevalence of low testosterone levels in male patients with schizophrenia. Eur Psychiatry. 2013;28:1.","journal-title":"Eur Psychiatry"},{"key":"8396_CR37","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1097\/01.yic.0000405927.79522.c5","volume":"26","author":"A Mendrek","year":"2011","unstructured":"Mendrek A, Bourque J, Champagne J, et al. Different role of sex steroid hormones in brain activations of schizophrenia patients and healthy controls. Int Clin Psychopharmacol. 2011;26:e166\u20137.","journal-title":"Int Clin Psychopharmacol"},{"issue":"8","key":"8396_CR38","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1017\/S003329170800319X","volume":"38","author":"N Bergemann","year":"2008","unstructured":"Bergemann N, Parzer P, Mundt C, et al. High bone turnover but normal bone mineral density in women suffering from schizophrenia. Psychol Med. 2008;38(8):1195\u2013201.","journal-title":"Psychol Med"},{"key":"8396_CR39","first-page":"B688","volume":"4","author":"CY Dhume","year":"2014","unstructured":"Dhume CY, Amonkar S, Menezes M. Role of reproductive hormones in schizophrenia. Int J Pharma Bio Sci. 2014;4:B688\u201393.","journal-title":"Int J Pharma Bio Sci"},{"issue":"3","key":"8396_CR40","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.schres.2015.07.034","volume":"168","author":"KM Allen","year":"2015","unstructured":"Allen KM, Purves-Tyson TD, Shannon Weickert C. Reproductive hormones and schizophrenia. Schizophr Res. 2015;168(3):601\u20132.","journal-title":"Schizophr Res"},{"issue":"6","key":"8396_CR41","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/mp.2015.11","volume":"20","author":"TW Weickert","year":"2015","unstructured":"Weickert TW, Weinberg D, Lenroot R, et al. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry. 2015;20(6):685\u201394.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"8396_CR42","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.bone.2007.11.008","volume":"42","author":"D Seriwatanachai","year":"2008","unstructured":"Seriwatanachai D, Thongchote K, Charoenphandhu N, et al. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand\/osteoprotegerin ratio. Bone. 2008;42(3):535\u201346.","journal-title":"Bone"},{"issue":"1","key":"8396_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/hup.1265","volume":"27","author":"MP Crews","year":"2012","unstructured":"Crews MP, Howes OD. Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. Hum Psychopharmacol. 2012;27(1):15\u201323.","journal-title":"Hum Psychopharmacol"},{"key":"8396_CR44","doi-asserted-by":"publisher","first-page":"385","DOI":"10.4088\/JCP.v69n0307","volume":"69","author":"T Kishimoto","year":"2008","unstructured":"Kishimoto T, Watanabe K, Shimada N, et al. Antipsychotic-Induced Hyperprolactinemia Inhibits the Hypothalamo-Pituitary-Gonadal Axis and Reduces Bone Mineral Density in Male Patients With Schizophrenia. J Clin Psychiatry. 2008;69:385\u201391.","journal-title":"J Clin Psychiatry"},{"key":"8396_CR45","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"P Glendenning","year":"2011","unstructured":"Glendenning P. Markers of Bone Turnover for the Prediction of Fracture Risk and Monitoring of Osteoporosis Treatment: A Need for International Reference Standards. Osteoporos Int. 2011;22:391\u2013420.","journal-title":"Osteoporos Int"},{"issue":"2","key":"8396_CR46","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391\u2013420.","journal-title":"Osteoporos Int"},{"key":"8396_CR47","doi-asserted-by":"publisher","first-page":"13598","DOI":"10.1038\/s41598-020-70668-w","volume":"10","author":"X Du","year":"2020","unstructured":"Du X, Ye F, Li J, et al. Altered levels of BMD, PRL, BAP and TRACP-5b in male chronic patients with schizophrenia. Sci Rep. 2020;10:13598.","journal-title":"Sci Rep"},{"key":"8396_CR48","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.schres.2013.04.015","volume":"147","author":"T Takahashi","year":"2013","unstructured":"Takahashi T, Uchida H, John M, et al. The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: findings from a longitudinal observational cohort. Schizophr Res. 2013;147:383\u20136.","journal-title":"Schizophr Res"},{"key":"8396_CR49","doi-asserted-by":"publisher","first-page":"S248","DOI":"10.1016\/j.eurpsy.2016.01.631","volume":"33","author":"C Franch","year":"2016","unstructured":"Franch C, Medina G, Ortega MD, et al. Problems in long-term treatment with atypical antipsychotics: hyperprolactinemia. Eur Psychiatry. 2016;33:S248\u20139.","journal-title":"Eur Psychiatry"},{"issue":"2","key":"8396_CR50","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.psychres.2013.04.026","volume":"209","author":"X Zhang","year":"2013","unstructured":"Zhang X, Bu R, Sha W, et al. Serum prolactin and smoking status in chronic antipsychotic-treated male patients with schizophrenia. Psychiatry Res. 2013;209(2):239\u201341.","journal-title":"Psychiatry Res"},{"issue":"12","key":"8396_CR51","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3109\/09513590.2012.683080","volume":"28","author":"Y Zhao","year":"2012","unstructured":"Zhao Y, Gan X, Luo P, et al. The risk of osteopenia in premenopausal women with various sellar tumors. Gynecol Endocrinol. 2012;28(12):945\u20138.","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"8396_CR52","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/YIC.0000000000000062","volume":"30","author":"CH Lin","year":"2015","unstructured":"Lin CH, Lin CY, Huang TL, et al. Sex-specific factors for bone density in patients with schizophrenia. Int Clin Psychopharmacol. 2015;30(2):96\u2013102.","journal-title":"Int Clin Psychopharmacol"},{"issue":"8","key":"8396_CR53","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s00198-012-1940-y","volume":"23","author":"V Yoon","year":"2012","unstructured":"Yoon V, Maalouf NM, Sakhaee K. The effects of smoking on bone metabolism. Osteoporos Int. 2012;23(8):2081\u201392.","journal-title":"Osteoporos Int"},{"key":"8396_CR54","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/joim.12366","volume":"277","author":"TLN Jarvinen","year":"2015","unstructured":"Jarvinen TLN, Michaelsson K, Aspenberg P, et al. Osteoporosis: the emperor has no clothes. J Intern Med. 2015;277:662\u201373.","journal-title":"J Intern Med"},{"issue":"2","key":"8396_CR55","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johnell, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005;16(2):155\u201362.","journal-title":"Osteoporos Int"},{"key":"8396_CR56","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.schres.2014.09.032","volume":"159","author":"K-Y Tsai","year":"2014","unstructured":"Tsai K-Y, Lee C-C, Chou Y-M, et al. The risks of major osteoporotic fractures in patients with schizophrenia: A population-based 10-year follow-up study. Schizophr Res. 2014;159:322\u20138.","journal-title":"Schizophr Res"},{"issue":"5","key":"8396_CR57","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/YCO.0b013e328355e1ac","volume":"25","author":"T Kishimoto","year":"2012","unstructured":"Kishimoto T, Hert MD, Carlson HE, et al. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry. 2012;25(5):415\u201329.","journal-title":"Curr Opin Psychiatry"},{"key":"8396_CR58","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.2741\/e575","volume":"E4","author":"F Milena","year":"2012","unstructured":"Milena F, Francesca S, Francesca V, et al. Role of obesity, alcohol and smoking on bone health. Front Biosci. 2012;E4:2586\u2013606.","journal-title":"Front Biosci"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08396-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08396-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08396-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:45:24Z","timestamp":1791517524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-08396-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8396"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08396-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9362646\/v1","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We declare that all experiments on human subjects were conducted in accordance with the Declaration of Helsinki and that all procedures were carried out with the adequate understanding and written consent of the subjects. All experimental protocols were approved by the Ethics Committee of Yangzhou WuTaiShan Hospital. Informed consent was obtained from all the participants and\/or their legal guardians. All methods were carried out in accordance with relevant guidelines and regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"774"}}